aTYR PHARMA (ATYR) Long-Term Investments (2015 - 2016)
aTYR PHARMA's (ATYR) quarterly Long-Term Investments came in at $4.0 million in Q4 2016, down 86.58% YoY from $29.8 million in Q1 2016, and down 61.25% on a QoQ basis from $10.3 million in Q3 2016.
aTYR PHARMA (ATYR) Long-Term Investments (2015 - 2016) Analysis & Trends
aTYR PHARMA (ATYR) has 2 years of Long-Term Investments data on file, last reported at $4.0 million in Q4 2016.
- Quarterly Long-Term Investments fell 86.58% year-over-year to $4.0 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $4.0 million (down 86.58% YoY) and the FY2016 annual result came in at $4.0 million, down 86.58% from the prior year.
- Long-Term Investments fell to $4.0 million in Q4 2016, from $10.3 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $44.7 million in Q2 2015 to a low of $4.0 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 4.00 Mn |
| Sep 30, 2016 | 10.33 Mn |
| Jun 30, 2016 | 12.66 Mn |
| Mar 31, 2016 | 25.56 Mn |
| Dec 31, 2015 | 29.81 Mn |
| Sep 30, 2015 | 28.01 Mn |
| Jun 30, 2015 | 44.74 Mn |